The U.S. Army developed a vaccine it says may protect against all COVID-19 variants.
The Walter Reed Army Institute of Research developed a 24-sided object to which it attached various spike proteins from coronavirus variants, Fox News reports. The vaccine has completed phase 1 of trials, but researchers have yet to test it against the Omicron variant.
The phase 1 human trials began in April of 2021 after two years of development. Scientists celebrated early data as encouraging and will publish results once the analysis is complete.
“This vaccine stands out in the COVID-19 vaccine landscape,” Dr. Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at Walter Reed Army Institute of Research, said.
One of the main points of interest is how the vaccine interacts with people who have already received a vaccination or had a previous infection.
WRAIR will work with a currently unnamed industry partner for a potential wider rollout, but that rollout likely won’t happen for a year.
